LUTATHERA®
LUTATHERA® (177Lu-DOTATATE) is a form of peptide receptor radionuclide therapy (PRRT) comprising of the somatostatin analogue octreotate (DOTATATE) and the radionuclide lutetium-177 (Lu-177), approved for use in adults with unresectable or metastatic, progressive, well-differentiated (grade 1 and grade 2), somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours (GEP-NETs).1
Reference
1. LUTATHERA®. Summary of Product Characteristics. Available at: https://www.ema.europa.eu/en/documents/product-information/lutathera-epar-product-information_en.pdf. Accessed January 2024.
AAA-Lu177-UK-2280 | January 2024
